Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back


Sergey Suchkov

Sechenov University, Russia

Biography

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD; in 1985 maintained his PhD at the I M Sechenov Moscow Medical Academy and in 2001, maintained his Doctor Degree at National Institute of Immunology , Russia. From 1987 through 1989 was a Senior Researcher at Koltzov Institute of Developmental Biology. From 1989 through 1995, he was the Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). He has been trained at: National Institute of Health; Wills Eye Hospital, Pennsylvania, USA; University of Florida in Gainesville; University of California San Francisco; Johns Hopkins University, Baltimore, MD, USA respectively. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a Chair, Department for Personalized and Translational Medicine, I M Sechenov First Moscow State Medical University. He is a Member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; European Association for Predictive, Preventive and Personalized Medicine (EPMA), Belgium; American Association for Research in Vision and Ophthalmology (ARVO); ISER (International Society for Eye Research); Personalized Medicine Coalition (PMC), Washington, USA.

Abstract

Abstract : Antibody-proteases as a novel biomarker and a unique target to suit translational tools to be applied for biodesign, bioengineering and regenerative medicine therapeutic for a treatment of EGFR-dependent breast cancer tumors